Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
The REScUE study compared two ustekinumab dosing intensification regimens after secondary loss of response in Crohn’s disease, finding no superiority of more frequent dosing regarding steroid-free remission at 48 weeks.
The US FDA’s unprecedented exemption of clinical efficacy studies for a ustekinumab biosimilar marks a transformative regulatory milestone, reshaping biosimilar development, market dynamics, and patient access worldwide.
Achieving disease clearance early after induction therapy with ustekinumab in ulcerative colitis patients predicts sustained clinical remission, symptom control, and improved quality of life over four years.